Menorrhagia Clinical Trials

Find Menorrhagia Clinical Trials Near You

The Effects of Tranexamic Acid on Anaemia, Menstrual Health and the Wellbeing of Women: an International Randomised, Placebo-controlled Trial Among Menstruating Women With Anaemia

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Anaemia is when the body does not have enough healthy red blood cells to carry oxygen. It is common in women because they lose blood every month during their periods. Anaemia can womwn make feel tired, weak, dizzy and out of breath. It can also make it harder to study, work or look after their family. If woman become pregnant with anaemia, it can cause problems for both mother and baby, such as early birth or heavy bleeding when giving birth. It is best to treat anaemia in young women well before they get pregnant. Doctors treat anaemia with iron and vitamins. But some people get side effects when taking iron tablets and so they stop taking them. Tranexamic acid (TXA) is a medicine used to treat heavy periods. The investigators of this study would like to find out if taking TXA with the usual iron and vitamin supplements is better at treating anaemia than taking iron and vitamin supplements alone. (Lay Summary)

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult women aged 18 years and older.

• Currently menstruating, with menstrual periods occurring at least every 38 days and lasting ≥2 days.

• Anaemia at screening, defined as hemoglobin (Hb) \<120 g/L by point-of-care finger prick test.

• Willing and able to provide informed consent.

• Able to attend in-person follow-up visits during the trial period.

⁃ Individuals with known thalassaemia and sickle cell disease are eligible to participate and take the trial treatment but will not be given standard of care iron supplementation unless it is prescribed by their own treating clinician. They will continue to receive their usual standard care.

Locations
Other Locations
Nigeria
University College Hospital
RECRUITING
Ibadan
Pakistan
Shifa Tameer e Millat University
NOT_YET_RECRUITING
Islamabad
United Republic of Tanzania
Mbeya College of Health and Allied Sciences, University of Dar es Salaam
NOT_YET_RECRUITING
Mbeya
Contact Information
Primary
Eni Balogun
woman3@lshtm.ac.uk
020 7958 8117
Backup
Professor Ian Roberts
woman3@lshtm.ac.uk
020 7958 8128
Time Frame
Start Date: 2026-08-10
Estimated Completion Date: 2028-09
Participants
Target number of participants: 4000
Treatments
Experimental: Tranexamic acid (TXA)
Tranexamic acid (TXA) 2 x 500 mg oral tablets, taken three times daily from the first to the last day of the menstrual period (maximum 5 days), for six consecutive menstrual cycles (up to a maximum of 9 months). Participants also receive standard of care oral iron and folic acid supplementation for three months from randomisation.
Placebo_comparator: Placebo
Matching placebo 2 x 500 mg oral tablets, taken three times daily from the first to the last day of the menstrual period (maximum 5 days), for six consecutive menstrual cycles (up to a maximum of 9 months). Participants also receive standard of care oral iron and folic acid supplementation for three months from randomisation.
Related Therapeutic Areas
Sponsors
Collaborators: Shifa Tameer-e-Millat University, Versailles Saint-Quentin-en-Yvelines University, University College Hospital, Ibadan, University of Dar es Salaam, Tanzania (Mbeya College of Health and Allied Sciences), Coefficient Giving, The Jon Moulton Charity Trust, University of Edinburgh
Leads: London School of Hygiene and Tropical Medicine

This content was sourced from clinicaltrials.gov